



UNITED STATES PATENT AND TRADEMARK OFFICE

ck

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/711,268	09/07/2004	George Piczenik		5267

30576 7590 02/01/2006

DR. GEORGE PIECZENIK
APT. 1F
412 EAST 55TH STREET
NEW YORK, NY 10022

EXAMINER

SHIRALI, SHYAM S

ART UNIT PAPER NUMBER

1654

DATE MAILED: 02/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/711,268	Applicant(s) PIECZENIK, GEORGE	
	Examiner Shyam Shirali	Art Unit 1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ____ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4 is/are pending in the application.
4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-4 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3 and 4 are rejected under 35 U.S.C. 112 second paragraph as being indefinite for failing to clearly indicate what type of therapy and diagnosis this peptide will be used.

Therefore, the claims are incomplete without the method steps.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 2 are rejected under U.S.C.102(b) as being anticipated by Ruben et. al.

(2002/0028449).

Applicant claims peptide HIPRT comprising in a lead compound having the same sequence.

Ruben et. al. anticipate the claimed invention (page 248 SEQ No ID 156) because Ruben et. al. teaches the isolation of human secreted proteins and peptide containing HIPRT as a subset of peptide SEQ ID NO156)

Further, he also uses the isolated peptide for treating disorders and diseases.

Therefore the reference is deemed to anticipate the claimed invention.

Art Unit: 1654

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4 are rejected under 35 U.S.C. 112 first paragraph, as failing to comply with the enablement requirement. The claims contains subject matter which was not described in the specification in such way as to enable one skilled in the art to which is pertains, or with which it is most nearly connected, to make and use/or use the invention. In the instant application, applicant receipt a method of using the peptide HIPRT for therapy and diagnosis.

The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in *Wands* states, "Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue', not 'experimentation'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations" (*Wands*, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

While all of these factors are considered, a sufficient amount for a *prima facie* case is discussed below.

(1) The nature of the invention and (2) the breadth of the claims:

The claims 3-4 are drawn to a method of using peptide HIPRT can be used in any therapy since the details of the therapy are not mentioned. Claim 4 is drawn to the method of using the peptide for diagnostic use. The applicant has not mentioned which type of diagnosis

Art Unit: 1654

or treatment this peptide can be used for, therefore the claims are extremely broad.

(3) The state of the prior art and (4) the unpredictability of the art.

The prior art of Ruben et. al. have shown that the peptides containing HIPRT sequence may be used for the various diseases and conditions.

HIPRT has been claimed for the therapy but not for any particular disease or diagnostic purposes and therefore the is highly unpredictable.

(5) The relative skill of those in the art:

The relative skill of those in the art is high.

(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:

The specifications provided gives no working examples to support the claims, the amount of guidance presented in the specification to practice the invention is quite inadequate. No guidance at all on how to use claimed protein for therapy or diagnosis.

(8) The quantity of experimentation necessary:

A great deal of experimentation would be required. All the work of reducing the invention to practice is left to others.

Considering the state of the art as discussed Ruben et.al. and high unpredictability and lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention.

It is the Examiner's position that one skilled in the art could not practice the invention commensurate in the scope of the claims without undue experimentation. It is also noted, considering the *a priori* unpredictability in the art with regard to practicing invention, use of

Art Unit: 1654

peptide HIPRT for any therapy of diagnostic purposes is not enabled.

Since there is no readily apparent use for the compositions other than therapy or diagnosis, claims 1 and 2 are also included in the rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shyam Shirali whose telephone number is (571)-272-5547. The examiner can normally be reached on 8.00am to 4.30pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Bruce Campell can be reached on (571) 272- 0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Shyam Shirali

Tel: (571) 272-5547

Rem :3D 10



BRUCE R. CAMPPELL, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600